Mr. Travis Doupe reports
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
Willow Biosciences Inc. has released the voting results from its annual general and special meeting of shareholders, held on July 26, 2024. A total of 27,685,611 common shares, representing approximately 21.74 per cent of the company's issued and outstanding shares, were represented at the meeting.
The shareholders approved the setting of the number of directors of Willow at five directors, and nominees were elected as directors of Willow for the ensuing year with the specific voting results being set out herein.
Votes for Votes withheld
Director Number % Number %
Donald Archibald 19,248,325 77.19% 5,686,936 22.81%
Al Foreman 24,905,181 99.88% 30,080 0.12%
Raffi Asadorian 21,273,181 85.31% 3,662,080 14.69%
Dr. Jim Lalonde 24,905,317 99.88% 29,944 0.12%
Dr. Chris Savile 24,905,182 99.88% 30,079 0.12%
In addition, shareholders approved the appointment of KPMG LLP as the company's auditor for the ensuing year (86.77 per cent of the votes cast being in favour). The shareholders also approved the grant of unallocated share awards issuable under Willow's share award incentive plan pursuant to the requirements of the Toronto Stock Exchange. For complete voting results on all matters approved at the meeting, please see the company's report of voting results dated July 26, 2024, available on SEDAR+.
About Willow Biosciences Inc.
Willow develops bio-based processes to manufacture ingredients for the pharmaceutical, food and beverage, and consumer markets. Willow's FutureGrown and BioOxi platforms enable large-scale production with sustainability at its core. Willow's research and development team has a proven record of developing and commercializing bio-based manufacturing processes and products to benefit its business-to-business partners and their customers.
© 2024 Canjex Publishing Ltd. All rights reserved.